BioSpace News Archive

Pfizer Inc. (NYSE: PFE) announced today further details regarding the proposed spin-off of its Upjohn Business and the subsequent combination of Mylan and the Upjohn Business to form Viatris Inc. As previously announced, Pfizer has set the close of business on November 13, 2020 as the record date for the spin-off, and the combination of Mylan and the Upjohn Business is expected to close on November 16, 2020. No action is re

-- Data demonstrate that patients enrolled in the GAIN Trial have baseline biomarkers consistent with Alzheimer’s disease and potential responders to atuzaginstat -- -- Press release issued in advance of CTAD presentation as an SEC exemption to the embargo policy, granted by the conference’s organizers --

Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the commercial launch of its Lumivascular products and completion of its first patient cases in Israel.

Halberd Corporation (OTC PINK: HALB ) reports its research team developed a second monoclonal antibody against Covid-19 SARS 2 disease antigens paving the way for development of a potentially more effective nasal spray. Additionally, Halberds continuing work on its new class of antibody doubles the performance capacity of a key functional parameter.

The AEGIS-II trial is evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) during the high-risk 90-day period following a heart attack

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that on November 4, 2020 it entered into a privately negotiated exchange and purchase agreement (the “Agreement”) with a holder of its currently outstanding 4.50% Convertible Senior Notes due 2024 (the “Existing 2024 Notes”). Pursuant to the Agreement, in exchange for $64,842,000 aggregate principal amount of Existing 2024 Notes held by the holder (which is currently con

Seagen Announces Multiple ADCETRIS ® (Brentuximab Vedotin) Presentations at the Upcoming ASH Annual Meeting - Five-Year Update to be Presented from ADCETRIS Phase 3 ECHELON-1 and ECHELON-2 Clinical Trials - - Additional Data Analyses Highlight Activities Across Broad ADCETRIS Development Program -

Novālent Biotech, Inc (‘Novālent’), a US biotechnology engineering firm, announces it is launching its patented surface disinfectant products in Australia and New Zealand. Novālent technology protects against bacteria and viruses on surfaces for up to 90 days. The antimicrobial is applied to surfaces by wiping, spraying, or fogging. Once dry, the surface remains protected even if touched or recontaminated multiple

Yield10 Bioscience, Inc. (NASDAQ: YTEN), an agricultural bioscience company, announced today that the Company will report its third quarter 2020 financial results and provide a corporate update on Thursday, November 12, 2020. Management will host a conference call on Thursday, November 12, 2020 at 4:30 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management’s formal remarks,

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today provided a clinical program update and reported financial results for the third quarter ended September 30, 2020. “Bellerophon continues to advance multiple development programs for its INOpulse ® inhaled nitric oxide therapy,” said Fabian Te